Shots:
- Esperion Therapeutics & ARCHIMED have entered a definitive agreement under which ARCHIMED-managed funds will acquire Esperion, delisting it from NASDAQ
- As per the deal, Esperion’s shareholders will receive $3.16/share in cash, plus the right to participate in CVR of ~$100M tied to future sales, valuing the transaction at up to ~$1.1B in fully diluted equity value assuming milestone achievement; closing expected in Q3’26
- CVR holders will receive $40M if 2027 US sales of bempedoic acid products exceed $350M, or payouts between $0–$40M for sales of $300M–$350M, plus $60M if annual US sales of bumetanide products reach ≥$160M by Dec 31, 2030
Ref: Globenewswire | Image: Esperion | Press Release
Related News: UCB to Acquire Candid Therapeutics for ~$2.2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
